366 related articles for article (PubMed ID: 32299640)
1. Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms.
Skala SL; Wang X; Zhang Y; Mannan R; Wang L; Narayanan SP; Vats P; Su F; Chen J; Cao X; Siddiqui J; Argani P; Cieślik MP; Giordano TJ; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Eur Urol; 2020 Jul; 78(1):63-74. PubMed ID: 32299640
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Intercalated Cell Markers KIT and
Mannan R; Wang X; Bawa PS; Zhang Y; Skala SL; Chinnaiyan AK; Dagar A; Wang L; Zelenka-Wang SB; McMurry LM; Daniel N; Cao X; Sangoi AR; Gupta S; Vaishampayan UN; Hafez KS; Morgan TM; Spratt DE; Tretiakova MS; Argani P; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Int J Surg Pathol; 2023 Sep; 31(6):1027-1040. PubMed ID: 36250542
[No Abstract] [Full Text] [Related]
3. FOXI1 expression in chromophobe renal cell carcinoma and renal oncocytoma: a study of The Cancer Genome Atlas transcriptome-based outlier mining and immunohistochemistry.
Tong K; Hu Z
Virchows Arch; 2021 Apr; 478(4):647-658. PubMed ID: 32812119
[TBL] [Abstract][Full Text] [Related]
4. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
[TBL] [Abstract][Full Text] [Related]
5. Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates.
Alaghehbandan R; Przybycin CG; Verkarre V; Mehra R
Asian J Urol; 2022 Jan; 9(1):1-11. PubMed ID: 35198391
[TBL] [Abstract][Full Text] [Related]
6. Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients-A Tale of Two Cities: Sequencing Analysis Reveals Dual Lineage Markers Capturing the 2 Cellular Populations of HOT.
Wang XM; Mannan R; Zhang Y; Chinnaiyan A; Rangaswamy R; Chugh S; Su F; Cao X; Wang R; Skala SL; Hafez KS; Vaishampayan U; Mckenney J; Picken MM; Gupta S; Alaghehbandan R; Tretiakova M; Argani P; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Am J Surg Pathol; 2024 Feb; 48(2):163-173. PubMed ID: 37994665
[TBL] [Abstract][Full Text] [Related]
7. L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma.
Alghamdi M; Chen JF; Jungbluth A; Koutzaki S; Palmer MB; Al-Ahmadie HA; Fine SW; Gopalan A; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Chen YB
Mod Pathol; 2024 May; 37(5):100467. PubMed ID: 38460672
[TBL] [Abstract][Full Text] [Related]
8. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
[TBL] [Abstract][Full Text] [Related]
9. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1.
Morini A; Drossart T; Timsit MO; Sibony M; Vasiliu V; Gimenez-Roqueplo AP; Favier J; Badoual C; Mejean A; Burnichon N; Verkarre V
Mod Pathol; 2022 Mar; 35(3):352-360. PubMed ID: 34531523
[TBL] [Abstract][Full Text] [Related]
10. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
Tjota MY; Wanjari P; Segal J; Antic T
Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
[TBL] [Abstract][Full Text] [Related]
11. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.
Ruiz-Cordero R; Rao P; Li L; Qi Y; Atherton D; Peng B; Singh RR; Kim TB; Kawakami F; Routbort MJ; Alouch N; Chow CB; Tang X; Lu W; Brimo F; Matin SF; Wood CG; Tannir NM; Wistuba II; Chen K; Wang J; Medeiros LJ; Karam JA; Tamboli P; Sircar K
Mod Pathol; 2019 Nov; 32(11):1698-1707. PubMed ID: 31231128
[TBL] [Abstract][Full Text] [Related]
12. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis.
Chen CV; Croom NA; Simko JP; Stohr BA; Chan E
Hum Pathol; 2022 Jan; 119():85-93. PubMed ID: 34800526
[TBL] [Abstract][Full Text] [Related]
13. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic and Molecular Characterization of Xanthomatous Giant Cell Renal Cell Carcinomas: Further Support for a Close Morphologic Spectrum to Eosinophilic Solid and Cystic Renal Cell Carcinomas.
Xu Y; Zhang X; Xia Q; Zhou Y; Wang X; Fang R; Wang Y; Tong Q; Chen J; Shi J; Fu Y; Rao Q
Am J Surg Pathol; 2024 Jun; 48(6):662-670. PubMed ID: 38595297
[TBL] [Abstract][Full Text] [Related]
15. Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma.
Kwon R; Argani P; Epstein JI; Lombardo KA; Wang X; Pierorazio PM; Mehra R; Matoso A
Am J Surg Pathol; 2021 Apr; 45(4):450-462. PubMed ID: 33239504
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
[TBL] [Abstract][Full Text] [Related]
18. Amylase α-1A (AMY1A): a novel immunohistochemical marker to differentiate chromophobe renal cell carcinoma from benign oncocytoma.
Jain S; Roy S; Amin M; Acquafondata M; Yin M; Laframboise W; Bastacky S; Pantanowitz L; Dhir R; Parwani A
Am J Surg Pathol; 2013 Dec; 37(12):1824-30. PubMed ID: 24225843
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Sequencing to Detect Deletion of RB1 and ERBB4 Genes in Chromophobe Renal Cell Carcinoma: A Potential Role in Distinguishing Chromophobe Renal Cell Carcinoma from Renal Oncocytoma.
Liu Q; Cornejo KM; Cheng L; Hutchinson L; Wang M; Zhang S; Tomaszewicz K; Cosar EF; Woda BA; Jiang Z
Am J Pathol; 2018 Apr; 188(4):846-852. PubMed ID: 29353061
[TBL] [Abstract][Full Text] [Related]
20. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
Huo L; Sugimura J; Tretiakova MS; Patton KT; Gupta R; Popov B; Laskin WB; Yeldandi A; Teh BT; Yang XJ
Hum Pathol; 2005 Mar; 36(3):262-8. PubMed ID: 15791570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
